Docetaxel trihydrate is the hydrated form of Docetaxel, a semi-synthetic chemotherapeutic agent belonging to the taxane class. It is derived from the needles of the European yew tree (Taxus baccata) and is used as an antimitotic agent to treat various solid tumors.
Docetaxel trihydrate is commonly used in the treatment of:
∙ Breast cancer
∙ Non-small cell lung cancer (NSCLC)
∙ Prostate cancer
∙ Gastric cancer
∙ Head and neck cancers
It works by stabilizing microtubules, thereby inhibiting cell division (mitosis), ultimately leading to cancer cell death.
Docetaxel trihydrate is typically administered via intravenous infusion under medical supervision, and the trihydrate form ensures better stability and solubility during formulation.
Parent: Docetaxel Trihydrate
Parent: Docetaxel Trihydrate
Parent: Docetaxel Trihydrate
Parent: Docetaxel Trihydrate
Parent: Docetaxel Trihydrate
Parent: Docetaxel / Docetaxel Trihydrate
Impurities in docetaxel trihydrate may arise from the complex multi-step synthesis, storage degradation, or formulation processes, and must be strictly controlled due to its narrow therapeutic index and cytotoxic nature.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Docetaxel trihydrate is used to treat various cancers, including:
Common side effects include:
Serious side effects (require close monitoring):
Liver function abnormalities
